Motorola: Paging Diagnostics
Executive Summary
Motorola is developing an expertise in microarray manufacturing to use as the jump-off point for a new life sciences initiative it hopes will turn into a high-margin, high-growth diagnostics business. It has spent $500 million in external investments to support the venture, including the $280 million acquisition of a clinical diagnostics start-up. But with its investors concerned with the recent downturn in demand in its core high-tech manufacturing businesses, the company is understandably reticent about touting the possibility of life sciences being its next big thing. On the other hand, should Motorola gain momentum and demonstrate an ability to tap the clinical diagnostics markets, the biochip initiative could ultimately become a broad-based point-of-care play, with the company drawing on its expertise in wireless communications to produce interactive handheld devices that would capture and transmit data to a remote site for analysis.
You may also be interested in...
OrthoSensor: Will Sensor-Enabled Data Transform Orthopedics?
OrthoSensor is trying to bring a data-driven revolution to orthopedics. It is building a three-legged platform, with intelligent instruments, intelligent implants, and analytics, all driven by sensor and other micro-electronics technology that feed back to surgeons vital data both intra- and post-operatively. Critical to its strategy: that improving outcomes in orthopedic surgery rests on developing better, data-rich surgical techniques, rather than novel implants made of new materials or design features.
Can Nanotech Be a Game-Changer for In Vitro Diagnostics?
People have awakened to the opportunities in diagnostics. Molecular information offers the potential for increased test sensitivity, and reduced upfront sample prep using nanotechnology could provide the means for many gene- and protein-based diagnostic tests to transition out of the central lab. Nanotech may also enable the use of newly discovered or newly usable biomarkers. Finally, unlike the traditional point-of-care model, a new wave of nanotech-based instruments could bring testing even closer to the patient.
Can Nanotech Be a Game-Changer for In Vitro Diagnostics?
People have awakened to the opportunities in diagnostics. Molecular information offers the potential for increased test sensitivity, and reduced upfront sample prep using nanotechnology could provide the means for many gene- and protein-based diagnostic tests to transition out of the central lab. Nanotech may also enable the use of newly discovered or newly usable biomarkers. Finally, unlike the traditional point-of-care model, a new wave of nanotech-based instruments could bring testing even closer to the patient.